Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trial

Sanofi’s Sarclisa, combined with standard care, significantly improves progression-free survival in newly diagnosed multiple myeloma patients eligible for stem cell transplant, as shown in a Phase III trial. It targets CD38, leading to cell death and immune-mediated destruction. Sarclisa, already approved for relapsed refractory multiple myeloma, aims for earlier treatment settings, competing with Johnson & Johnson’s Darzalex.